ResearcherUniversity of California San DiegoActive in the last 2 years
Cristina Salmerón
Matched on ORCID iD 0000-0003-2259-3807; OpenAlex author ID A5083553980. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 10
2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 2 papers · 2026: 2 papers
Papers 5
- Corrigendum to "Histamine H1 receptor: a potential therapeutic target for pancreatic ductal adenocarcinoma". Co-author DOI 10.1016/j.jpet.2026.104305↗
- Histamine H1 receptor: A target to treat pancreatic ductal adenocarcinoma (PDAC) by repurposing approved H1-antihistamines? First author DOI 10.46439/signaling.4.094↗
- Histamine H1 Receptor: A potential therapeutic target for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.jpet.2025.103573↗
- Pancreatic Ductal Adenocarcinoma, β-blockers, and Antihistamines: A Clinical Trial Is Needed. Co-author DOI 10.1093/function/zqae050↗
- GPCRs in pancreatic adenocarcinoma: Contributors to tumour biology and novel therapeutic targets. First author DOI 10.1111/bph.15028↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Paul A. Insel · 5 shared papers, 2020–2026 · strength 1.34
- Paper Histamine H1 receptor: A target to treat pancreatic ductal adenocarcinoma (PDAC) by repurposing approved H1-antihistami… DOI 10.46439/signaling.4.094↗
- Paper Pancreatic Ductal Adenocarcinoma, β-blockers, and Antihistamines: A Clinical Trial Is Needed. DOI 10.1093/function/zqae050↗
- Paper Corrigendum to "Histamine H1 receptor: a potential therapeutic target for pancreatic ductal adenocarcinoma". DOI 10.1016/j.jpet.2026.104305↗
- Peter James McCormick · 4 shared papers, 2025–2026 · strength 1.18
- Paper Histamine H1 receptor: A target to treat pancreatic ductal adenocarcinoma (PDAC) by repurposing approved H1-antihistami… DOI 10.46439/signaling.4.094↗
- Paper Pancreatic Ductal Adenocarcinoma, β-blockers, and Antihistamines: A Clinical Trial Is Needed. DOI 10.1093/function/zqae050↗
- Paper Corrigendum to "Histamine H1 receptor: a potential therapeutic target for pancreatic ductal adenocarcinoma". DOI 10.1016/j.jpet.2026.104305↗
- Andrew M. Lowy · 3 shared papers, 2025–2026 · strength 0.87
- Paper Histamine H1 receptor: A target to treat pancreatic ductal adenocarcinoma (PDAC) by repurposing approved H1-antihistami… DOI 10.46439/signaling.4.094↗
- Paper Corrigendum to "Histamine H1 receptor: a potential therapeutic target for pancreatic ductal adenocarcinoma". DOI 10.1016/j.jpet.2026.104305↗
- Paper Histamine H1 Receptor: A potential therapeutic target for pancreatic ductal adenocarcinoma. DOI 10.1016/j.jpet.2025.103573↗
- Krishna Sriram · 3 shared papers, 2020–2026 · strength 0.65
- Paper Corrigendum to "Histamine H1 receptor: a potential therapeutic target for pancreatic ductal adenocarcinoma". DOI 10.1016/j.jpet.2026.104305↗
- Paper Histamine H1 Receptor: A potential therapeutic target for pancreatic ductal adenocarcinoma. DOI 10.1016/j.jpet.2025.103573↗
- Paper GPCRs in pancreatic adenocarcinoma: Contributors to tumour biology and novel therapeutic targets. DOI 10.1111/bph.15028↗
- Elena Tomás Bort · 2 shared papers, 2025–2026 · strength 0.49
- Richard Philip Grose · 2 shared papers, 2025–2026 · strength 0.49
- Jonathan Weitz · 2 shared papers, 2025–2026 · strength 0.49
- Hervé Tiriac · 2 shared papers, 2025–2026 · strength 0.49
- Erica K. Sloan · 1 shared paper, 2025 · strength 0.30
- Jillian G. Baker · 1 shared paper, 2025 · strength 0.30
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.